Systemic safety of ranibizumab for diabetic macular edema: Meta-analysis of randomized trials

Retina

Volumn 34, Issue 4, 2014, Pages 629-635

  Yanagida, Yasuko ^a   Ueta, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE ACETATE;

CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; HEART INFARCTION; HUMAN; LASER COAGULATION; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897491077     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000116     Document Type: Review

References (29)

1. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-1070.
2. Ym Paulus, Gariano RF. Diabetic retinopathy: a growing concern in an aging population. Geriatrics 2009;64:16-20.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report 1. Arch Ophthalmol 1985; 103:1796-1806.
4. Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (Lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Cur Eye Res 2012;37:661-670.
5. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangio-genic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2012:CD007419.
6. Higgins J, Green S. Assessing Risk of Bias in Included Studies. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 ed. Oxford, United Kingdom: Cochrane Collaboration; 2008:672.
7. Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. Stroke 2007;38:1404-1410.
8. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with anti-resorptive agents. J Clin Endocrinol Metab 2002;87:1586-1592.
9. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013;131:283-293.
10. Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagu-lation. Retina 2011;31:1009-1027.
11. Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131:139-145.
12. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-614.
13. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-2151.
14. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic mac-ular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-2318.
15. Messias A, Ramos Filho JA, Messias K, et al. Electroretino-graphic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Doc Ophthalmol 2012;124:225-236.
16. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (Six Months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181.e1.
17. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating rani-bizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.e35.
18. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
19. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicen-ter phase II study. Diabetes Care 2010;33:2399-2405.
20. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
21. Efficacy and safety of ranibizumab (intravitreal injections) in patients with visual impairment due to diabetic macular edema (REVEAL). NCT00989989. Study results are available at ClinicalTrials.gov. Accessed May 15, 2013.
22. Rosenfeld P, Brown D, Heier J, et al. Ranibizumab for neo-vascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
23. Brown DM, Kaiser P, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
24. Antoszyk A, Tuomi L, Chung C, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145:862-874.
25. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009;116:362.
26. Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012; 32:1821-1828.
27. Kemp A, Preen DB, Morlet N, et al. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina 2013;33: 920-927.
28. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357:1821-1828.
29. Gerstein HC, Ambrosius WT, Danis R, et al. Diabetic ret-inopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care 2013;36: 1266-1271.